News | September 25, 2013

Majority of Patients Who Qualify for Lifesaving Heart Treatment Do Not Receive It

September 25, 2013 — A new clinical study of patients who died of sudden cardiac arrest, a usually fatal condition that causes the heart to stop beating, shows the majority who qualified to receive potentially lifesaving treatment did not receive it.

Researchers led by Sumeet Chugh, M.D., associate director of the Cedars-Sinai Heart Institute, examined medical records of 2,093 patients who died of sudden cardiac arrest and found that only 488 patients, or about 20 percent, were medically evaluated to see if they met the criteria to receive an implantable cardiac defibrillator, which can shock a stopped heart into beating. Of those 488 patients, 92 were eligible to receive this treatment. However, further analysis showed that just 12 patients of those who were eligible received a defibrillator.

“That tells us that even people who meet the guidelines, for some reason, are not getting this therapy,” said Chugh, the Pauline and Harold Price Chair in Cardiac Electrophysiology. “The data show that most people aren’t screened for sudden cardiac arrest, but even when they are eligible, they still are not getting proper treatment.”

The analysis of data from the Oregon Sudden Unexpected Death Study is published online by Circulation, the medical journal of the American Heart Assn., and is scheduled to appear in the printed edition of the publication dated Oct. 15, 2013.

“The purpose of guidelines is to deploy treatments in the right people,” Chugh said. “It’s not a question of more defibrillators or fewer, but a question of providing defibrillators to the patients who need it the most.”

Guidelines are standards of treatment established by a consensus of medical experts. Additionally, the U.S. Centers for Medicare & Medicaid Services establish criteria for which patients qualify for certain interventions, such as defibrillator implantation.

Currently, the guidelines call for patients to receive defibrillators if their heart’s ejection fraction — a measure of the heart’s ability to pump blood — is less than 35 percent. Of the 448 patients who did receive proper screening for sudden cardiac arrest, 304 or nearly 68 percent, were ineligible for a defibrillator because their ejection fraction was too high.

“The pumping function of the heart has to be weak to meet the defibrillator guidelines,” Chugh said. “Most of the people in our study don’t have a low ejection fraction, but they still died of sudden cardiac arrest, which leads me to suggest that we need to take another look at the guidelines.”

Although the general public often uses the terms “sudden cardiac arrest” and “heart attack” interchangeably, they are distinctly different medical conditions.

A heart attack is caused when there is a blockage, such as a blood clot, in one or more arteries of the heart, preventing the heart from receiving enough blood, resulting in damage to the heart muscle.

Sudden cardiac arrest, which accounts for half of all deaths caused by heart disease, is triggered by an electrical malfunction in the heart that causes an irregular heartbeat, called arrhythmia. Arrhythmia causes a disruption in the flow of blood to other organs throughout the body. Without treatment, the patient can die in seconds.

Chugh said more analysis is needed to determine why patients with low ejection fractions did not receive implantable defibrillators.

“Perhaps they had other health problems that drove the decision-making process, or possibly many didn’t have health insurance or access to care,” Chugh said. “It could be a variety of reasons.”

For more information: www.newswise.com

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init